Home

ALAN D FRAZIER

CIK 1018534 · last filed 2014-03-21

ALAN D FRAZIER is a corporate insider who has filed 18 SEC Form 4 insider transactions across 2 companies since 2007. 14 SEC filings were submitted jointly with Nathan R Every.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

18

Lifetime Open-Market Net

$0

Filer Profile

Related Filers
Nathan R Every — 14 joint filings, latest 2018-05-15
Nader J Naini — 14 joint filings, latest 2018-05-15
Patrick J Heron — 12 joint filings, latest 2018-05-15
ANAPTYSBIO, INC — 8 joint filings, latest 2018-05-15
FHM V, LLC — 7 joint filings, latest 2018-05-15
FHM V, LP — 7 joint filings, latest 2018-05-15
Frazier Healthcare V, LP — 7 joint filings, latest 2018-05-15
James N Topper — 5 joint filings, latest 2015-06-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CADENCE PHARMACEUTICALS INC (CADX) Delisted Director 4,692,387 — — $0 10 2014-02-21
Alexza Pharmaceuticals Inc. (ALXA) Delisted Director 4,685 — — $0 7 2011-10-27

Recent Filings

18 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2014-03-21 — Mixed −8,613,185 -$120.58M
2014-02-21 CADENCE PHARMACEUTICALS INC (CADX) Delisted Mixed +764,684 -$17 EDGAR
2013-06-13 CADENCE PHARMACEUTICALS INC (CADX) Delisted Grant (A) — $0 EDGAR
2012-06-14 CADENCE PHARMACEUTICALS INC (CADX) Delisted Grant (A) — $0 EDGAR
2011-10-27 Alexza Pharmaceuticals Inc. (ALXA) Delisted — — $0 EDGAR
2011-06-17 CADENCE PHARMACEUTICALS INC (CADX) Delisted Grant (A) — $0 EDGAR
2010-06-17 CADENCE PHARMACEUTICALS INC (CADX) Delisted Grant (A) — $0 EDGAR
2010-05-20 Alexza Pharmaceuticals Inc. (ALXA) Delisted Grant (A) — $0 EDGAR
2010-01-28 Alexza Pharmaceuticals Inc. (ALXA) Delisted Grant (A) +21,008 $0 EDGAR
2009-06-26 CADENCE PHARMACEUTICALS INC (CADX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 18
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.